Candel Therapeutics (CADL) Shares Outstanding (Diluted Average) (2021 - 2025)

Candel Therapeutics has disclosed Shares Outstanding (Diluted Average) across 5 years of filings, most recently posting $53.0 million for Q4 2025.

• Shares Outstanding (Diluted Average) for Q4 2025 came in at $53.0 million, up 67.19% year-over-year; the trailing twelve-month figure through Dec 2025 was $53.0 million (up 67.19% YoY), and the FY2025 annual result was $53.0 million, up 67.19% from the prior year.
• Shares Outstanding (Diluted Average) came in at $53.0 million for Q4 2025 at Candel Therapeutics, up from $31.7 million in the prior quarter.
• In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $53.0 million in Q4 2025 to a low of $11.7 million in Q2 2021.
• The 5-year median for Shares Outstanding (Diluted Average) is $28.9 million (2023), against an average of $28.8 million.
• Across the five-year window, Shares Outstanding (Diluted Average) soared 145.81% in 2022 and grew 0.38% in 2023, its largest moves.
• Candel Therapeutics' Shares Outstanding (Diluted Average) stood at $18.9 million in 2021, then soared by 52.72% to $28.8 million in 2022, then gained by 0.39% to $28.9 million in 2023, then grew by 9.47% to $31.7 million in 2024, then jumped by 67.19% to $53.0 million in 2025.
• The last three Shares Outstanding (Diluted Average) figures came in at $53.0 million (Q4 2025), $31.7 million (Q4 2024), and $32.0 million (Q3 2024), per Business Quant data.